EyePoint Pharmaceuticals (EYPT) Proxy filing summary

Executive summary

• Advanced DURAVYU, a sustained delivery therapy for retinal diseases, through pivotal Phase 3 trials in wet AMD and DME, with over 900 patients enrolled and strong safety and efficacy data reported in 2025.

• Anticipates topline data for wet AMD trials in mid-2026 and DME trials in late 2027, with NDA submission planned if clinical success is achieved.

• Maintains a strong financial position with over $300 million in cash and investments at year-end 2025 and no debt, funding operations into Q4 2027.

• Scaled up commercial manufacturing at a CGMP facility in Massachusetts to support potential US launch of DURAVYU.

Voting matters and shareholder proposals

• Election of eight directors to serve until the 2027 Annual Meeting.

• Approval of Amendment No. 3 to the 2023 Long-Term Incentive Plan, increasing authorized shares by 4,900,000.

• Advisory vote on executive compensation (say-on-pay).

• Ratification of Deloitte & Touche LLP as independent auditor for fiscal 2026.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board will reduce to eight members after the 2026 meeting, with all nominees having significant industry, financial, and governance experience.

• All committees (Audit, Compensation, Governance and Nominating, Compliance) are composed entirely of independent directors.

• Board leadership is separated between Chair and CEO roles.

• Annual self-evaluations and regular refreshment of board composition are conducted.